Search Within

Andrew D Zelenetz

  1. "Adult Leukemia"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (21)
  3. Research Letter (3)
  4. Book Section (1)
Groups
  1. Adult Leukemia (58)
  2. Center for Hematologic Malignancies (58)
  3. Department of Medicine (58)
  4. Hematologic Malignancies, Division of (58)
  5. Lymphoma (58)
  6. GSK Faculty (31)

More Groups

People
  1. Anthony Mato (33)
  2. Lindsey Roeker (30)
  3. Maria Palomba (19)
  4. Ahmet Dogan (15)
  5. Meghan Thompson (15)
  6. Ariela Noy (14)

More People

Years
  1. 2024 (1)
  2. 2023 (6)
  3. 2022 (7)
  4. 2021 (5)
  5. 2020 (9)
  6. 2019 (6)

More Years

Publications
  1. Blood (26)
  2. Journal of Clinical Oncology (5)
  3. Blood Advances (4)
  4. Clinical Cancer Research (3)
  5. Leukemia (3)
  6. Leukemia and Lymphoma (3)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. American Society of Clinical Oncology (5)
  3. Nature Publishing Group (5)
  4. American Association for Cancer Research (4)
  5. Taylor & Francis Group (3)
  6. Wiley Blackwell (2)

More Publishers

Results (58)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
    Meeting Abstract

    Lewis, D. J.; Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutzu, K.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma
    Journal Article

    Wang, M. L.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; Flinn, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection
    Journal Article

    Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save